Friday, October 9, 2026
In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@adjoro) cover Phase 3 results for retatrutide with up to 28.3% average weight loss at 80 weeks. They explain dosing, tolerability and what remains unproven for heart and kidney outcomes and how retatrutide compares with current GLP-1 options. They also break down a federal proposal to modernize airline emergency kits around nine life threatening categories with airline level discretion. Plus: they discuss a growing pediatric heart valve, the return of Doc, Best Medicine, Chicago Med and Grey’s Anatomy, and more.
New to Medlines? Check out the full playlist: https://www.youtube.com/playlist?list=PLR-tmjMS1yRo
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit https://www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At:
https://www.medlinespod.com/sources
Medlines is a Human Content Production